Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Clinical trial NCT05146219 · COMPLETED

Trial details

NCT number: NCT05146219
Sponsor: TYK Medicines, Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC EGFR Activating Mutation Brain Metastases Leptomeningeal Metastasis

Start date: 2022-04-02
Primary completion: 2024-03-21
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.